Wegener's Granulomatosis or Microscopic Polyangiitis
Conditions
Brief summary
This is a perspective, Phase IV, multi-center, single arm, open-label, interventional study in adult participants with Wegener's granulomatosis (granulomatosis with polyangiitis \[GPA\]) or microscopic polyangiitis. Participants will be treated with rituximab (Ristova) and glucocorticoids. Rituximab will be administered by intravenous (IV) infusion at a dose of 375 milligrams per meter square (mg/m\^2) body surface area once weekly during Weeks 1 to 4. Participants will also receive one or three pulses of methylprednisolone (1000 milligram \[mg\] each), followed by a tapering dose of oral prednisolone (start dose of 1 mg per kilogram per day). The dose of oral prednisone will be reduced as per evaluation by the investigator till the participant is completely off the drug. The participants will be followed up for duration of 6 months from the date of starting rituximab therapy with three follow-up visits at Days 52, 112 and 172. All adverse events occurring during this period will be captured.
Interventions
DRUGMethylprednisolone
Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
DRUGPrednisone
Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day \[mg/kg/day\]) at the discretion of investigator given daily until participants are off the drug.
DRUGRituximab
Rituximab will be administered at 375 milligrams per meter square (mg/m\^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or non-pregnant, non-nursing female * Diagnosed with Wegener's granulomatosis or Microscopic polyangiitis according to the definitions of the Chapel Hill Consensus Conference * Participants with either newly diagnosed or relapsing disease * Participants must have active disease as per the BVAS/WG greater than equal to (\>/=) 3 that would normally require treatment with cyclophosphamide (CYC) * Participants willing to practice medically acceptable contraception during and 1 year after the completion of rituximab therapy * Participants must have severe disease i.e. one or more of the major BVAS/WG items depicting severity or disease severe enough to require treatment with CYC. * Participants must be positive for either proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCA) or myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) at the screening
Exclusion criteria
* History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies * Participants in a severely immunocompromised state * Participants with severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease * Participants having active severe infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections * Participants who had a live vaccine fewer than 4 weeks before first dose of rituximab * Any other condition which puts the participant to undue risk for rituximab therapy as per local prescribing information or Investigator's judgment * Participants with any previous treatment with rituximab * Participants with any previous treatment with alemtuzumab * Participants who have had treatment with infliximab within the previous 3 months * Participants who have had treatment with adalimumab within the previous 2 months * Participants who have had treatment with etanercept within the previous month * Participants with any other investigational medication within the previous month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants With Adverse Events and Serious Adverse Events | Baseline up to 6 months |
| Percentage of Participants Who Achieved a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) Score of 0 and Successfully Completed Prednisone Taper at 6 Months | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Number of Severe Flares | At Months 2, 4, 6 |
| Percentage of Participants With Refractory Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis (AAV) Who Achieved BVAS/WG Score of 0 and Successfully Completed Prednisone Taper at 6 Months | 6 months |
| Number of Limited Flares | At Months 2, 4, 6 |
| Percentage of Participants Who Achieved a BVAS/WG Score of 0 During Treatment With Prednisone at a Dose of Less Than (<) 10 mg/day | 6 months |
| Percentage of Participants Who Achieved and Maintained Partial Remission (Defined as Having a BVAS/WG of 1 or 2) | 6 months |
Countries
India
Outcome results
None listed